Loading
A phase 1/2 trial of Saruparib, Enzalutamide, Abiraterone acetate in prostate cancer, run by AstraZeneca, active and no longer recruiting.
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT05367440 by AstraZeneca, with 174 participants enrolled, started 2022-06-02 and due to reach its primary completion in 2031-04-11. Interventions recorded: AZD5305, Enzalutamide, Abiraterone Acetate, Darolutamide, Apalutamide. Conditions listed: Metastatic Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Darolutamide, Apalutamide, Abiraterone acetate, Enzalutamide.
Shares Apalutamide, Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Saruparib, AstraZeneca, Prostate cancer.
Shares Saruparib, AstraZeneca, Prostate cancer.
Shares Darolutamide, Apalutamide, Abiraterone acetate, Enzalutamide.
Shares Apalutamide, Abiraterone acetate, Prostate cancer.
Shares Saruparib, AstraZeneca, Prostate cancer.
Shares Darolutamide, Abiraterone acetate, Prostate cancer.